I kēia manawa, aia ka COVID-19 i ke kūlana maʻi maʻi a puni ka honua. ʻO ka superposition o nā ʻano like ʻole Delta a me Omicron, e hopena i ka hoʻonui mau ʻana o kā lākou hiki ke hoʻouna. Ma waena o nā nalu hou o COVID-19, i ka hoʻohui ʻana i ke kano COVID-19, ka hoʻomohala ʻana i nā lāʻau lapaʻau COVID-19 waha a me nā ʻano hoʻokolohua wikiwiki, maʻalahi a me nā ʻano hou i lilo i koi hou no ka pale ʻana a me ka mālama ʻana i nā maʻi maʻi. ʻO Viva Biotech Holdings XLement, hoʻopukapuka ʻia a hoʻokomo ʻia e Viva BioInnovator, ua kūpaʻa i ka hana ʻana i nā lāʻau lapaʻau COVID-19 waha a me ka hoʻāʻo ʻana i ka maʻi virus, e hāʻawi ana i ka hakakā ʻana i ka maʻi maʻi COVID-19.

Ian 2022, ua hoʻolaha ka Medicines Patent Pool (MPP) ua hoʻopaʻa inoa ʻo ia i nā ʻaelike me kekahi mau ʻoihana hana maʻamau e like me Zhejiang Langhua Pharmaceutical Co., Ltd., ka lālā o Viva biotech holdings no ka hana ʻana o ka waha COVID-19 antiviral lāʻau molnupiravir a hāʻawi i nā ʻāina haʻahaʻa haʻahaʻa a me waena (LMICs) he 105 e hoʻomaʻamaʻa i ke komo ʻana o ka honua no ka molnupiravir a kākoʻo i ka pale ʻana a me ka mālama ʻana i ka maʻi maʻi kūloko. ʻElima mau ʻoihana e kālele ana i ka hana ʻana i nā mea maka, 13 mau hui e hana i nā mea ʻelua a me ka lāʻau lapaʻau i hoʻopau ʻia a ʻo 9 mau hui e hana i ka lāʻau i pau.

ʻO ka Medicines Patent Pool (MPP) he hui olakino lehulehu i kākoʻo ʻia e United Nations e hana ana e hoʻonui i ke komo ʻana i, a hoʻomaʻamaʻa i ka hoʻomohala ʻana i nā lāʻau ola ola no nā ʻāina haʻahaʻa a me waena. ʻO MPP a me MSD, ka inoa kālepa o Merck & Co., Inc Kenilworth NJ USA ua kau inoa i kahi ʻaelike laikini manawaleʻa ma ʻOkakopa 2021. Ma lalo o nā ʻōlelo o ka ʻaelike, MPP, ma o ka laikini i hāʻawi ʻia e MSD, e ʻae ʻia e ʻae hou aku i ka laikini ʻole. nā sublicences i nā mea hana a hoʻololi i ke kahua hana no ka hoʻolako ʻana i ka molnupiravir i hoʻopaʻa ʻia i ka maikaʻi i nā ʻāina i uhi ʻia e ka MPP Licence, ma lalo o ka mana hoʻoponopono kūloko.

ʻO Molnupiravir (MK-4482 a me EIDD-2801) kahi ʻano noiʻi, hoʻokele waha ʻia o kahi analog ribonucleoside ikaika e pale ai i ka hana hou ʻana o SARS-CoV-2 (ke kumu kumu o COVID-19). ʻO Molnupiravir e hoʻomohala nei ʻo MSD me ka Ridgeback Biotherapeutics, ʻo ia ka lāʻau antiviral waha mua i loaʻa no ka maʻi COVID-19. Ua hōʻike ka ʻikepili mai ka Phase 3 MOVe-OUT i ka mālama mua ʻana me ka molnupiravir i hōʻemi nui i ka pilikia o ka hale maʻi a i ʻole ka make i ka nui o ka pilikia, nā pākeke ʻaʻole i hoʻopaʻa ʻia me COVID-19.

Wahi a MPP, ua hōʻike maikaʻi nā hui i hāʻawi ʻia i ka sublicence i ko lākou hiki ke hoʻokō i nā koi o MPP e pili ana i ka hiki ke hana, ka hoʻokō hoʻoponopono, a me ka hiki ke hoʻokō i nā kūlana honua no nā lāʻau lapaʻau maikaʻi. ʻO ka ʻae i hāʻawi ʻia iā Langhua Pharmaceutical e MPP e hōʻike ana i kahi hōʻoia kiʻekiʻe a me ka hoʻomaopopo ʻana i kāna hana hoʻomohala a me ka hoʻonui ʻana i nā API, hoʻolako i ka hoʻomau, GMP a me ka ʻōnaehana EHS.

Ma Malaki 2nd, 2022, ua loaʻa iā Xlement, kahi ʻoihana biochip NanoSPR kūpaʻa a me nā mea hana biotech i hoʻopuka mua ʻia a incubated e Viva BioInnovator, i loaʻa ka leka hoʻomaopopo o ka hāʻawi ʻana i ka loiloi hana mai ka Ministry of Science and Technology of the People's Republic of China. ʻO kāna papahana "R&D a me Mass Production of NanoSPR COVID-19 Particle Test Kit" kekahi o nā papahana koʻikoʻi o ka papahana "Public Safety Risk Prevention and Control and Emergency Response Technology and Equipment" e lawelawe ana i kahi ʻāpana koʻikoʻi i ke kī COVID-19- noiʻi ʻepekema pili e holo nei ma Kina. Me kona holo kūleʻa i ka nānā ʻana, ua hōʻoia ʻia ʻo Xlement's COVID-19 Test Kit e ka European Union CE no ka hana nui e hiki mai ana a e hoʻohana koke ʻia.

Hoʻohana ʻia ma ka ʻenehana chip NanoSPR kūʻokoʻa, ua hoʻomohala ʻo Xlement i ka pahu hoʻāʻo no nā ʻāpana COVID-19, e ʻae i ka hoʻāʻo ʻana i hoʻokahi ʻanuʻu o nā antigen virus lehulehu no 96 mau laʻana i loko o 15 mau minuke, a ua kokoke ka naʻau i ka hoʻāʻo ʻana i hoʻokahi antigen. Hōʻike kēia ʻano i nā pōmaikaʻi nui i hoʻohālikelike ʻia i nā ʻenehana hoʻāʻo viral nucleic acid: hiki ke hoʻohana ʻia no ka hoʻāʻo ponoʻī ʻana ma ka home, pōkole ia i ka manawa hoʻāʻo nui, no laila, hoʻemi nui i ke kumukūʻai o ka hoʻāʻo ʻana i nā reagents a me ka hana. Me ka hoʻohana hou ʻana i ka ʻenehana NanoSPR i ka hoʻāʻo COVID-19 i hoʻomohala ʻia e Xlement, manaʻo mākou e ʻike i ka maʻalahi o ka maʻi maʻalahi o nā laʻana i manaʻo ʻia a me ka nānā wikiwiki ʻana ma ka pūnaewele ma ka nui.

He aha e lawe ʻia mai kēia ʻatikala:

On March 2nd, 2022, Xlement, a devoted NanoSPR biochip and instruments biotech company that previously invested and incubated by Viva BioInnovator, received the notice of passing the performance evaluation from the Ministry of Science and Technology of the People´s Republic of China.
Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non-exclusive sublicences to manufacturers and diversify the manufacturing base for the supply of quality-assured molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.
Amid the repeated waves of COVID-19, in addition to COVID-19 vaccine, the development of effective oral COVID-19 drugs and rapid, simple and innovative testing methods have also become a new demand for current epidemic prevention and control.